Sector News

GSK sells drug rights back to Amgen

December 16, 2015
Life sciences

Last April, Amgen took back most of the marketing rights to osteoporosis med Prolia that it had previously granted to GlaxoSmithKline. Now, it’s taking back the rest of them–and the rights to a couple of other drugs, too.

The California biotech is reacquiring licenses to Prolia, Xgeva–a related antifracture drug for cancer patients–and colon cancer therapy Vectibix in 48 countries, Amgen said in a statement. Among them are Brazil, China, Colombia, Hong Kong, Israel, Singapore, South Korea, Taiwan and Thailand, which Amgen regards as “key expansion markets,” CEO Robert Bradway said in a statement.

Amgen will foot undisclosed milestone payments to GSK, which netted $111 million in 2014 sales on the trio. After the transition, the meds will be padding Amgen’s top line, boosting last year’s sales hauls of $1.03 billion for Prolia, $1.22 billion for Xgeva and $505 million for Vectibix.

Glaxo has been holding rights to Prolia and Xgeva since 2009, and Vectibix since 2010, but as it said last April–when it agreed to return Prolia marketing duties in countries including Switzerland, Russia and Mexico–letting Amgen take them off its hands would allow it to focus on its own new launches.

The British drugmaker has plenty of those ongoing, and it needs to make them work. To help fill the void left by declining sales of respiratory behemoth Advair, the company has rolled out a slate of new respiratory treatments over the past couple of years, including COPD meds Breo and Anoro. Its most recent FDA approval came last month with a thumbs up for Nucala, green-lighted to treat patients with a form of severe asthma.

Amgen, meanwhile, can use the extra revenue from its three sellers as it shores up its defenses against biosimilars. Novartis’ Zarxio is already working to whittle away market share from aged giant Neupogen, and the Swiss drugmaker and others are prepping future competitors to a couple of its other older blockbusters, Neulasta and Enbrel.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”